Abstract:Background This study aimed to observe the difference in risk of polymyxin B-induced acute kidney injury with or without dose adjustment by patients’ renal function. Method A retrospective cohort analysis was carried out for patients who were treated with polymyxin B in Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine from November 2018 to October 2019. Patients were divided into adjusted dosage group and non-adjusted dosage group depended on dosage adjustment with renal function or not. A comparison of acute kidney injury incidence between the two groups was the primary outcome of this research. The secondary outcome included hospital length of stay, microbiological cure, clinical cure, and 30-day mortality. Result A total of 115 patients met the requirements of this study and were included in the analysis. Thirty-five patients were included in the non-adjusted dosage group and 80 in the adjusted dosage group. Patients from both groups had similar characteristics. The total daily dose of polymyxin B in the Non-adjusted dosage group was significantly higher than the adjusted dosage group (1.98 mg/kg/d vs 1.59 mg/kg/d, P =0.001). For the primary outcome of this research, no significant difference in the incidence of acute kidney injury was observed in these two groups (47.5% vs 37.14%, P =0.304), as well as the secondary outcomes, including hospital length of stay, microbiological cure, clinical cure, 30-day mortality. Conclusion Dosing adjustment renally could not lower the risk of polymyxin B-induced acute kidney injury significantly. A non-adjusted dosing strategy of polymyxin B is recommended when patients suffered from various levels of renal impairment. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The authors received no specific funding for this paper. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by Ruijin Hospital Institutional Review Board and has been performed in accordance with the ethical standards laid down in Declaration of Helsinki 1964 and its later amendments or comparable ethical standards. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data and material used and/or analyzed during the current study are available from the corresponding author on reasonable request. * PMB : polymyxin B MDR : multiple drug resistant AKI : acute kidney injury PK/PD : pharmacokinetic/pharmacodynamic CrCl : creatinine clearance sCr : serum creatinine LOS : length of stay APACHE II : Acute Physiology and Chronic Health Evaluation II CRE : Carbapenem-Resistant Enterobacteriaceae RCT : Randomized Controlled Trial TDM : therapeutic drug monitoring.

Risk Factors for Nephrotoxicity Associated with Polymyxin B Therapy in Chinese Patients.

Risk Factors for Polymyxin B-associated Acute Kidney Injury

Use Of Polymyxin B In Patients With Renal Impairment: A Retrospective Examination Of 5 Cases

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>

Higher Incidence of Neurotoxicity and Skin Hyperpigmentation in Renal Transplant Patients Treated with Polymyxin B

Prevalence of Polymyxin-Induced Nephrotoxicity and Its Predictors in Critically Ill Adult Patients: A Meta-Analysis.

Risk Factors for Polymyxin B-associated Acute Kidney Injury in Patients with Severe Gram-Negative Bacterial Infections

Early Use of Polymyxin B Reduces the Mortality of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infection

Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity

Pharmacokinetic/pharmacodynamic Adequacy of Polymyxin B Against Extensively Drug-Resistant Gram-negative Bacteria in Critically Ill, General Ward and Cystic Fibrosis Patient Populations.

Analysis of risk factors of polymyxin B-associated acute kidney injury in intensive care unit patients with severe infection

Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study

Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects

A Retrospective Analysis of Polymyxin B Combined with Tigecycline in the Treatment of Multi-Drug Resistance Klebsiella Pneumoniae Infection: Hypertension Increases the Incidence of Acute Kidney Injury

Factors Affecting the Effectiveness and Safety of Polymyxin B in the Treatment of Gram-negative Bacterial Infections: A Meta-Analysis of 96 Articles

Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or Without Renal Insufficiency

Risk of Polymyxin B-induced Acute Kidney Injury in Non-adjusted Dose Versus Adjusted Dose based on Renal Function: a retrospective cohort study

Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections